This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Medical Information

Administration of DARZALEX FASPRO – Use of a Filter

Last Updated: 05/31/2024

SUMMARY  

  • Use of a filter is not required for appropriate administration of DARZALEX FASPRO commercial product. However, a filter was utilized in the DARZALEX FASPRO clinical studies for all dose preparations per the investigational product preparation instructions.1 The types of filter supplies permitted and utilized in DARZALEX FASPRO clinical studies are summarized in the table: Filter Supplies Used in DARZALEX FASPRO Clinical Studies.
  • DARZALEX FASPRO commercial product is supplied ready to use.2
  • To prepare DARZALEX FASPRO, withdraw 15 mL from the vial into a syringe.2
  • After the solution of DARZALEX FASPRO is withdrawn into the syringe, replace the transfer needle with a syringe closing cap.2
  • To avoid needle clogging, attach the hypodermic injection needle or subcutaneous infusion set to the syringe immediately prior to injection.2

Filter Supplies Used in DARZALEX FASPRO Clinical Studies1
Type of Filter
Filter Pore Size
Filter Size
Material of Construction
Disk Filtera
0.45 μm
33 mm
PVDF or PES
1.2 μm
25 mm
PES
5 μm
25 mm
PVDF or PES
Filter Needle
5 μm
1.2 mm, 18-19 G
1-1.5” needle
Nylon
Filter Spike
5 μm
25 mm
Acrylic-copolymer
membrane/nylon
Abbreviations: PES, polyethersulfone; PVDF, polyvinylidene fluoride.aIf a disk filter is used during preparation, attach an appropriately sized general use sterile preparation needle to the filter.

PRODUCT LABELING

Please refer to the following sections of the Full Prescribing Information that are relevant to

your inquiry: DOSAGE AND ADMINISTRATION, PREPARATION AND ADMINISTRATION.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 10 May 2024.

 

References

1 Data on File. Technical document Investigational Product Preparation and Administration Instructions for Filtered JNJ-54767414 for Subcutaneous Administration. Janssen Research & Development, LLC. TV-TEC-94323; 2022.  
2 DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf.